Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade + melphalan + prednisone (VMP) in relapsed/refractory multiple myeloma
2007-006123-13Phase 2Completed
- Sponsor
- Fondazione EMN Italy
- Start
- Mar 2008
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by Fondazione EMN Italy. Primary endpoint: Safety and partial response rate with VMP. Started Mar 2008; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2007-006123-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006123-13.